Xiansi Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiansi Zeng has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
Jinjing Jia
Research Center of Neuroscience, Jiaxing University Medical College, Jiaxing 314001, China
12 shared publicationsJin-Jing Jia
Research Center of Neuroscience, Jiaxing University Medical College, Jiaxing, China
10 shared publications- Jing Jia
Research Center of Neuroscience, Jiaxing University Medical College, No. 118 Jiahang Road, Jiaxing, 314001, Zhejiang Province, China.
8 shared publications - Li Li
Department of Physiology, Medical College of Jiaxing University, Jiaxing, Zhejiang, 314000, China
7 shared publications Guangtao Xu
Judicial Expertise Center, Jiaxing University, Jiaxing, 314001, China
5 shared publications- Jie Bai
Medical school, Kunming University of Science and Technology
5 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by IMR Press in Journal of Integrative Neuroscience
- Vol. 25 (10)
Epigenetic Gene-Environment Interactions in Parkinson’s Disease
Background: Parkinson’s disease (PD) is the second most common neurodegenerative disorder, characterized by the progressive loss of dopaminergic neurons in the substantia nigra. While genetic mutations and environmental exposures have both been established as risk factors for PD, emerging evidence has implicated epigenetic modifications as key mediators of gene-environment interactions involved in the pathogenesis of PD. Objective: This review aims to systematically characterize the epigenetic regulatory mechanisms that bridge the effects of environmental neurotoxicants and genetic susceptibility in PD, providing a comprehensive synthesis of the current understanding of their functional crosstalk at a molecular level. Key Findings: Environmental factors drive the pathogenesis of PD through abnormal DNA methylation, dynamic imbalances in histone modification, and non-coding RNA regulatory networks. Here, we detail the mechanisms by which environment-induced epigenetic shifts give rise to the dysregulation of key PD-associated genes, including SNCA, PRKN (PARK2), PARK7 (DJ-1), and LRRK2. This epigenetic dysregulation subsequently exacerbates downstream pathological events, such as mitochondrial dysfunction, impaired autophagy, endoplasmic reticulum stress, and neuroinflammation. Conclusion: Systematically exploring epigenetic gene-environment interactions offers detailed insight into the etiology of PD. Given the potential reversibility of specific epigenetic modifications, targeting these pathways may offer a prospective avenue for neuroprotective research. However, further rigorous investigation remains essential to evaluate the clinical viability of these mechanisms as reliable biomarkers or therapeutic targets.
- 14 October 2026
- Published by IMR Press in Journal of Integrative Neuroscience
- Vol. 25 (10)
Open AccessEpigenetic Gene-Environment Interactions in Parkinson’s Disease
Background: Parkinson’s disease (PD) is the second most common neurodegenerative disorder, characterized by the progressive loss of dopaminergic neurons in the substantia nigra. While genetic mutations and environmental exposures have both been established as risk factors for PD, emerging evidence has implicated epigenetic modifications as key mediators of gene-environment interactions involved in the pathogenesis of PD. Objective: This review aims to systematically characterize the epigenetic regulatory mechanisms that bridge the effects of environmental neurotoxicants and genetic susceptibility in PD, providing a comprehensive synthesis of the current understanding of their functional crosstalk at a molecular level. Key Findings: Environmental factors drive the pathogenesis of PD through abnormal DNA methylation, dynamic imbalances in histone modification, and non-coding RNA regulatory networks. Here, we detail the mechanisms by which environment-induced epigenetic shifts give rise to the dysregulation of key PD-associated genes, including SNCA, PRKN (PARK2), PARK7 (DJ-1), and LRRK2. This epigenetic dysregulation subsequently exacerbates downstream pathological events, such as mitochondrial dysfunction, impaired autophagy, endoplasmic reticulum stress, and neuroinflammation. Conclusion: Systematically exploring epigenetic gene-environment interactions offers detailed insight into the etiology of PD. Given the potential reversibility of specific epigenetic modifications, targeting these pathways may offer a prospective avenue for neuroprotective research. However, further rigorous investigation remains essential to evaluate the clinical viability of these mechanisms as reliable biomarkers or therapeutic targets.
- 17 June 2026
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 49 (6) , 820-862
Therapeutic potential of glycyrrhizic acid in inflammation-related diseases: from HMGB1-oriented molecular insights to preclinical application
Chronic inflammation drives the pathogenesis of diverse disorders, yet current anti-inflammatory strategies often lack mechanistic selectivity. Glycyrrhizic acid (GL), a major triterpenoid saponin from Glycyrrhiza species, exhibits broad anti-inflammatory effects, but its mechanism has been viewed as non-specific. In this review, we propose an integrated framework positioning high-mobility group box 1 (HMGB1) as one major molecular hub for GL's action. Mechanistically, our molecular docking analysis suggests that GL may interact with the Box B domain of HMGB1 andmay potentially interfere with its engagement with TLR4 and RAGE, thereby orchestrating a cascade inhibition of downstream NF-κB, MAPK, and NLRP3 inflammasome pathways. Beyond this core signaling axis, we systematically analyze how GL context-dependently modulates macrophage polarization, monocyte-derived macrophage differentiation, and Th17/Treg balance. We further synthesize its effects across liver, autoimmune, metabolic, oncologic, neurological, and renal diseases, revealing shared mechanisms and disease-specific adaptations. Finally, we critically evaluate translational bottlenecks-including isomer-specific bioavailability, the pseudoaldosteronism risk, and formulation challenges-and propose strategies to overcome them. By shifting from a descriptive summary to a mechanism-centered, integrative analysis, this review provides a conceptual framework for developing GL as a multitarget anti-inflammatory agent, while acknowledging its limitations including low oral bioavailability, microbiota-dependent metabolism, pseudoaldosteronism risk, and limited clinical evidence.
- 17 June 2026
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 49 (6) , 820-862
Therapeutic potential of glycyrrhizic acid in inflammation-related diseases: from HMGB1-oriented molecular insights to preclinical application
Chronic inflammation drives the pathogenesis of diverse disorders, yet current anti-inflammatory strategies often lack mechanistic selectivity. Glycyrrhizic acid (GL), a major triterpenoid saponin from Glycyrrhiza species, exhibits broad anti-inflammatory effects, but its mechanism has been viewed as non-specific. In this review, we propose an integrated framework positioning high-mobility group box 1 (HMGB1) as one major molecular hub for GL's action. Mechanistically, our molecular docking analysis suggests that GL may interact with the Box B domain of HMGB1 andmay potentially interfere with its engagement with TLR4 and RAGE, thereby orchestrating a cascade inhibition of downstream NF-κB, MAPK, and NLRP3 inflammasome pathways. Beyond this core signaling axis, we systematically analyze how GL context-dependently modulates macrophage polarization, monocyte-derived macrophage differentiation, and Th17/Treg balance. We further synthesize its effects across liver, autoimmune, metabolic, oncologic, neurological, and renal diseases, revealing shared mechanisms and disease-specific adaptations. Finally, we critically evaluate translational bottlenecks-including isomer-specific bioavailability, the pseudoaldosteronism risk, and formulation challenges-and propose strategies to overcome them. By shifting from a descriptive summary to a mechanism-centered, integrative analysis, this review provides a conceptual framework for developing GL as a multitarget anti-inflammatory agent, while acknowledging its limitations including low oral bioavailability, microbiota-dependent metabolism, pseudoaldosteronism risk, and limited clinical evidence.
- 27 February 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 248, 117853
The therapeutic potential of cytisine and its derivatives in disorders of the central nervous system
- 27 February 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 248, 117853
The therapeutic potential of cytisine and its derivatives in disorders of the central nervous system
- Open Access
- 13 May 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-14
Thioredoxin-1 inhibits NLRP3-mediated pyroptosis by regulating TXNIP in models of Alzheimer’s disease
Alzheimer’s disease (AD) is the most common neurodegenerative disease characterized by memory loss. Our recent study has demonstrated that thioredoxin-1 (Trx-1) could protect neurons via repressing NLRP1‑mediated neuronal pyroptosis in AD models. However, whether Trx-1 could inhibit NLRP3 activation is largely unknown. Here, we found that AAV-mediated Trx-1 overexpression significantly inhibited NLRP3-mediated pyroptosis in the hippocampus of APP/PS1 mice. A mouse hippocampal neuron HT22 cell line overexpressing Trx-1 was successfully obtained through lentivirus transfection. Further study showed that Trx-1 overexpression protected HT22 cells against the neurocytotoxicity of Aβ25−35. Consistently with the results of in vivo experiments, overexpression of Trx-1 remarkedly inhibited the activation of NLRP3. In the contrary, knockdown of Trx-1 by siRNA transfection further aggravated the activation of NLRP3. Mechanistically, Trx-1 overexpression significantly inhibited the increase of thioredoxin-interacting protein (TXNIP) in in vivo and in vitro and weakened the interaction between TXNIP and NLRP3. Taken together, Trx-1 inhibits NLRP3-mediated pyroptosis by regulating TXNIP expression and its interaction with NLRP3 in AD models.
- 13 May 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-14
Open AccessThioredoxin-1 inhibits NLRP3-mediated pyroptosis by regulating TXNIP in models of Alzheimer’s disease
Alzheimer’s disease (AD) is the most common neurodegenerative disease characterized by memory loss. Our recent study has demonstrated that thioredoxin-1 (Trx-1) could protect neurons via repressing NLRP1‑mediated neuronal pyroptosis in AD models. However, whether Trx-1 could inhibit NLRP3 activation is largely unknown. Here, we found that AAV-mediated Trx-1 overexpression significantly inhibited NLRP3-mediated pyroptosis in the hippocampus of APP/PS1 mice. A mouse hippocampal neuron HT22 cell line overexpressing Trx-1 was successfully obtained through lentivirus transfection. Further study showed that Trx-1 overexpression protected HT22 cells against the neurocytotoxicity of Aβ25−35. Consistently with the results of in vivo experiments, overexpression of Trx-1 remarkedly inhibited the activation of NLRP3. In the contrary, knockdown of Trx-1 by siRNA transfection further aggravated the activation of NLRP3. Mechanistically, Trx-1 overexpression significantly inhibited the increase of thioredoxin-interacting protein (TXNIP) in in vivo and in vitro and weakened the interaction between TXNIP and NLRP3. Taken together, Trx-1 inhibits NLRP3-mediated pyroptosis by regulating TXNIP expression and its interaction with NLRP3 in AD models.
- Open Access
- 25 November 2024
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 288, 117411
Noise exposure-induced the cerebral alterations: From emerging evidence to antioxidant-mediated prevention and treatment
- 25 November 2024
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 288, 117411
Open AccessNoise exposure-induced the cerebral alterations: From emerging evidence to antioxidant-mediated prevention and treatment
- Open Access
- 23 November 2024
- Published by Springer Nature in Molecular Neurobiology
- Vol. 62 (5) , 6627
Correction: Thioredoxin-1 Protects Neurons Through Inhibiting NLRP1-Mediated Neuronal Pyroptosis in Models of Alzheimer’s Disease
- 23 November 2024
- Published by Springer Nature in Molecular Neurobiology
- Vol. 62 (5) , 6627
Open AccessCorrection: Thioredoxin-1 Protects Neurons Through Inhibiting NLRP1-Mediated Neuronal Pyroptosis in Models of Alzheimer’s Disease
- Open Access
- 28 September 2024
- Published by Springer Nature in Molecular Neurobiology
- Vol. 62 (5) , 6626
Correction: Thioredoxin-1 Protects Neurons Through Inhibiting NLRP1-Mediated Neuronal Pyroptosis in Models of Alzheimer’s Disease
- 28 September 2024
- Published by Springer Nature in Molecular Neurobiology
- Vol. 62 (5) , 6626
Open AccessCorrection: Thioredoxin-1 Protects Neurons Through Inhibiting NLRP1-Mediated Neuronal Pyroptosis in Models of Alzheimer’s Disease
- 2 September 2024
- Published by Elsevier in Science of The Total Environment
- Vol. 952, 175879
CD36-mediated ROS/PI3K/AKT signaling pathway exacerbates cognitive impairment in APP/PS1 mice after noise exposure
- 2 September 2024
- Published by Elsevier in Science of The Total Environment
- Vol. 952, 175879
CD36-mediated ROS/PI3K/AKT signaling pathway exacerbates cognitive impairment in APP/PS1 mice after noise exposure
- 8 July 2024
- Published by Springer Nature in Molecular Neurobiology
- Vol. 61 (11) , 9723-9734
Thioredoxin-1 Protects Neurons Through Inhibiting NLRP1-Mediated Neuronal Pyroptosis in Models of Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common neurodegenerative disease all over the world. In the last decade, accumulating proofs have evidenced that neuroinflammation is intimately implicated in the pathogenesis of AD and activation of NOD-like receptor family pyrin domain–containing 1 (NLRP1) inflammasome can induce neuronal pyroptosis and in turn lead to neuronal loss in AD. Thioredoxin-1 (Trx-1), a multifunctional molecule with anti-inflammation in human tissues, displays crucial neuroprotective roles in AD. Our previous research preliminarily found that Trx-1 inhibition enhanced the expression of NLRP1, caspase-1, and gasdermin D (GSDMD) in Aβ25–35-treated PC12 cells. However, it is largely unknown if Trx-1 can inhibit NLRP1-mediated neuronal pyroptosis in AD neurons. In this study, it was verified that the protein levels of NLRP1, caspase-1, and GSDMD were significantly increased in Aβ25–35-treated mouse HT22 and primary hippocampal neurons. Suppression of Trx-1 with PX-12, a selective inhibitor of Trx-1, or Trx-1 knockdown further activated NLRP1-mediated neuronal pyroptosis. On the contrary, lentivirus infection–mediated Trx-1 overexpression in differentiated PC12 cells dramatically reversed expression of NLRP1, caspase-1, and GSDMD. Furthermore, Trx-1 overexpression mediated by adeno-associated virus in the hippocampal tissues of APP/PS1 mice likewise attenuated the activation of NLRP1-mediated neuronal pyroptosis, as well as reduced the hippocampal deposition of Aβ and ameliorated the cognitive function of APP/PS1 mice. In conclusion, this article predicates a novel molecular mechanism by which Trx-1 exploits neuroprotection through attenuating NLRP1-mediated neuronal pyroptosis in AD models, suggesting that Trx-1 may be a promising therapeutic target for AD.
- 8 July 2024
- Published by Springer Nature in Molecular Neurobiology
- Vol. 61 (11) , 9723-9734
Thioredoxin-1 Protects Neurons Through Inhibiting NLRP1-Mediated Neuronal Pyroptosis in Models of Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common neurodegenerative disease all over the world. In the last decade, accumulating proofs have evidenced that neuroinflammation is intimately implicated in the pathogenesis of AD and activation of NOD-like receptor family pyrin domain–containing 1 (NLRP1) inflammasome can induce neuronal pyroptosis and in turn lead to neuronal loss in AD. Thioredoxin-1 (Trx-1), a multifunctional molecule with anti-inflammation in human tissues, displays crucial neuroprotective roles in AD. Our previous research preliminarily found that Trx-1 inhibition enhanced the expression of NLRP1, caspase-1, and gasdermin D (GSDMD) in Aβ25–35-treated PC12 cells. However, it is largely unknown if Trx-1 can inhibit NLRP1-mediated neuronal pyroptosis in AD neurons. In this study, it was verified that the protein levels of NLRP1, caspase-1, and GSDMD were significantly increased in Aβ25–35-treated mouse HT22 and primary hippocampal neurons. Suppression of Trx-1 with PX-12, a selective inhibitor of Trx-1, or Trx-1 knockdown further activated NLRP1-mediated neuronal pyroptosis. On the contrary, lentivirus infection–mediated Trx-1 overexpression in differentiated PC12 cells dramatically reversed expression of NLRP1, caspase-1, and GSDMD. Furthermore, Trx-1 overexpression mediated by adeno-associated virus in the hippocampal tissues of APP/PS1 mice likewise attenuated the activation of NLRP1-mediated neuronal pyroptosis, as well as reduced the hippocampal deposition of Aβ and ameliorated the cognitive function of APP/PS1 mice. In conclusion, this article predicates a novel molecular mechanism by which Trx-1 exploits neuroprotection through attenuating NLRP1-mediated neuronal pyroptosis in AD models, suggesting that Trx-1 may be a promising therapeutic target for AD.
- Open Access
- 14 December 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1345663
Corrigendum: Advances in the roles of glycyrrhizic acid in cancer therapy
Corrigendum: Advances in the roles of glycyrrhizic acid in cancer therapy
- 14 December 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1345663
Open AccessCorrigendum: Advances in the roles of glycyrrhizic acid in cancer therapy
Corrigendum: Advances in the roles of glycyrrhizic acid in cancer therapy